Review the side-effects of Ethinyl Estradiol and Levonorgestrel as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the ...
PRINCETON, N.J., April 30, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that a post hoc analysis of the Phase 3 SECURE Trial ...
PRINCETON, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the U.S. commercial launch of Twirla ® (levonorgestrel and ...
Twirla (levonorgestrel and ethinyl estradiol) transdermal system is now available as a method of contraception for use in women of reproductive potential with a BMI Twirla® (levonorgestrel and ethinyl ...
NORTH WALES, Pa., Sept. 24, 2013 /PRNewswire/ -- Teva Women's Health, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd., today announced that the recently approved Quartette™ ...
TWIRLA is indicated as a method of contraception for use in women of reproductive potential with a BMI 30 kg/m2 for whom a combined hormonal contraceptive is appropriate. Limitations of Use Consider ...
Teva Women’s Health, Inc., a U.S.-based subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its New ...
Shares of Glenmark Pharma climbed 1.7 percent intraday Monday on receiving final approval from the USFDA for its extended cycle oral contraceptives. Advisory Alert: It has come to our attention that ...
Please provide your email address to receive an email when new articles are posted on . In 2011, approximately 45% of the more than 6 million annual pregnancies in the United States were unintended, ...
A model assessing 8 hormonal contraceptive methods found that lower pregnancy costs for the etonogestrel implant and levonorgestrel intrauterine device offset their higher acquisition costs. To ...
Twirla ® is a new non-daily, non-invasive contraceptive approved in the U.S. PRINCETON, N.J., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq: AGRX) (Agile or the Company), a ...
FRAZER, Pa.--(BUSINESS WIRE)--Teva Women’s Health, Inc., a U.S.-based subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) ...